Abstract
ObjectivesTo evaluate clinical response by baseline disease duration using 2-year data from the AMPLE trial.MethodsPatients were randomised to subcutaneous abatacept 125 mg weekly or adalimumab 40 mg bi-weekly, with background...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have